Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase

Yohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, Alexandra O'Keefe, Andrea Endimiani, Robert A. Bonomo

Research output: Contribution to journalArticle

20 Citations (Scopus)


Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

Original languageEnglish
Pages (from-to)3159-3161
Number of pages3
JournalAntimicrobial agents and chemotherapy
Issue number7
Publication statusPublished - 01-07-2009
Externally publishedYes


All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this